Compare MYGN & MBUU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MYGN | MBUU |
|---|---|---|
| Founded | 1991 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Marine Transportation |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.5M | 554.5M |
| IPO Year | 1995 | 2014 |
| Metric | MYGN | MBUU |
|---|---|---|
| Price | $7.17 | $28.65 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 13 | 8 |
| Target Price | $12.58 | ★ $33.57 |
| AVG Volume (30 Days) | ★ 1.1M | 289.9K |
| Earning Date | 11-03-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.98 |
| Revenue | $825,300,000.00 | ★ $830,714,000.00 |
| Revenue This Year | $0.10 | N/A |
| Revenue Next Year | $5.28 | $7.03 |
| P/E Ratio | ★ N/A | $29.04 |
| Revenue Growth | 0.21 | ★ 11.54 |
| 52 Week Low | $3.76 | $24.07 |
| 52 Week High | $16.63 | $45.02 |
| Indicator | MYGN | MBUU |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 53.69 |
| Support Level | $6.93 | $27.04 |
| Resistance Level | $7.38 | $28.98 |
| Average True Range (ATR) | 0.39 | 1.39 |
| MACD | 0.03 | 0.40 |
| Stochastic Oscillator | 39.88 | 87.99 |
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Malibu Boats is a designer and manufacturer of power boats in the United States. It is a market leader in performance sport boats, sold under its Malibu and Axis brands. It acquired Cobalt Boats, a producer of sterndrive boats, in 2017, and Pursuit Boats, which makes high end offshore and outboard motorboats in 2018. In 2021, it purchased Maverick Boat Group, a seller of flat fishing boats, with exposure to bay, dual console, and center console boats. Malibu has also expanded into boat trailers and accessories, and in 2020, began producing its own engines for its performance sport boats.